Ucla-CDU cfar - overall: project summary/abstract: this application is a resubmission for a new cfar that is a partnership between ucla and CDU
Active Project Grant Awarded Last action
- Award ID
- P30AI152501
- Recipient
-
University Of California, LOS Angeles UEI RN64EPNH8JC6 Part of State Of California Controllers Office
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $11,996,147
Award facts
- Assistance listing
- 93.397 Cancer Centers Support Grants
- Completion date 92% complete
- Funding
-
- $11,028,827.00 Federal
- $967,320.00 Non-federal
- Funding agency
- National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health, Department of Health and Human Services
- Place of performance
- Los Angeles, CA 90024, USA
Award details come from USAspending.gov.
Description
Our overarching goal is to create a nimble multi-institutional infrastructure that promotes equity and will connect and support investigators affiliated with both institutions to advance critical HIV science. The ucla-CDU cfar will strengthen and amplify the impact of existing research activities and launch new partnerships across LOS angeles and globally through our focus on three themes: we will stop HIV by preventing new HIV infections (PREVENTION), reducing morbidity among people living with HIV (TREATMENT) and developing strategies for eradication (art-free remission). This grant will fund aids-related activities and programs conducted by investigators at ucla, CDU and our affiliated institutions, which include harbor-ucla medical center in torrance; the ucla care clinic and the VA greater LOS angeles healthcare system in westwood; the ucla vine street clinic in west hollywood; and the drew cares, the CDU push coalition and the MLK OASIS clinic at CDU. These facilities are at ground zero for the aids epidemic in LOS angeles county, with the greatest number of persons living with HIV residing in the neighborhoods directly served by our hospitals and clinics. In addition to the facilities and programs based in LOS angeles, researchers at ucla and CDU have extensive partnerships with HIV programs around the globe that are aimed at building global capacity. The cfar will enhance our ability to deliver research at the interface of community by reaching communities most in need and by bringing to bear the talent of CDU and ucla researchers to address problems from a multi-disciplinary perspective while mentoring the next generation who better reflect the diversity of communities being served. The overall organization of the ucla-CDU cfar will allow US to efficiently and effectively manage aids research activities by harnessing the diverse expertise in our cfar, and by including linkages to community- based clinician investigators and communities. The action plan for the first year of requested support includes 6 cores and 1 scientific working group (SWG): the administrative core, developmental core, centralized laboratory support core, humanized mouse and gene therapy core, community engagement and clinical informatics core, clinical science core, and a translational research in substance use SWG. Relevance: research into the pathogenesis, TREATMENT and social aspects of HIV disease is required to end the epidemic. The ucla-CDU cfar seeks to catalyze and expand HIV research by providing the infrastructure to connect, support and enhance the capacity of investigators affiliated with ucla and CDU. This will be accomplished by stimulating the conduct and dissemination of high impact multidisciplinary research aimed at the NIH priorities of preventing new HIV infections (PREVENTION), reducing morbidity among people living with HIV (TREATMENT) and developing strategies for eradication (art-free remission).
Transactions
| Action | Federal | Non-federal | Date |
|---|---|---|---|
| Amendment | $0 | $0 | |
| Amendment | $147,825 | $0 | |
| Amendment | $56,700 | $0 | |
| Amendment | $151,916 | $0 | |
| Amendment | $51,700 | $0 | |
| Amendment | $527,698 | $0 | |
| Amendment | $527,698 | $0 | |
| Amendment | $188,574 | $0 | |
| Amendment | $188,574 | $0 | |
| Amendment | $188,574 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $0 | $0 | |
| Amendment | $51,700 | $0 | |
| Amendment | $147,825 | $0 | |
| Amendment | $2,057,141 | $0 | |
| Amendment | $267,000 | $0 | |
| Amendment | $755,595 | $0 | |
| Amendment | $755,595 | $755,595 | |
| Amendment | $755,595 | $0 | |
| Amendment | $755,595 | $0 | |
| Amendment | $755,595 | $0 | |
| Amendment | $56,700 | $0 | |
| Amendment | $63,900 | $0 | |
| Amendment | $63,900 | $63,900 | |
| Amendment | $63,900 | $0 | |
| Amendment | $56,700 | $0 | |
| Amendment | $63,900 | $0 | |
| Amendment | $51,700 | $0 | |
| Amendment | $147,825 | $0 | |
| Amendment | $200,000 | $0 | |
| Amendment | $85,500 | $0 | |
| Amendment | $1,261,777 | $0 | |
| Amendment | $63,900 | $0 | |
| Amendment | $267,000 | $0 | |
| Amendment | $51,700 | $0 | |
| Amendment | $147,825 | $147,825 | |
| Original award | $51,700 | $0 |
Show all 39
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Charles R. Drew University Of Medicine And Science | $40,158 | |
| Partners In Hope | $41,094 | |
| Charles R. Drew University Of Medicine And Science | $124,326 | |
| Charles R. Drew University Of Medicine And Science | $75,600 | |
| University Of Alabama At Birmingham | $23,805 | |
| LOS Angeles Centers For Alcohol And Drug Abuse | $36,336 | |
| University Of Alabama At Birmingham | $48,101 | |
| The Rand Corporation | $255,780 | |
| Lundquist Institute For Biomedical Innovation At Harbor-Ucla Medical Center | $105,851 | |
| Charles R. Drew University Of Medicine And Science | $2,423,130 |
Quick answers
Who received award P30AI152501?
P30AI152501 was awarded to University Of California, LOS Angeles by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on April 8, 2022.
How much is award P30AI152501 worth?
$11,996,147 has been obligated on P30AI152501: $11,028,827 in federal funding and $967,320 in non-federal funding.
Which agency awarded P30AI152501?
National Institute of Allergy and Infectious Diseases (National Institutes of Health) awarded P30AI152501, with funding from National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health).
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award